<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534520</url>
  </required_header>
  <id_info>
    <org_study_id>SFP-RBR001</org_study_id>
    <nct_id>NCT01534520</nct_id>
  </id_info>
  <brief_title>Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women</brief_title>
  <acronym>LIVIIN</acronym>
  <official_title>Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate if self-inserted intravaginal 2% lidocaine gel is
      effective at decreasing pain during intrauterine device insertion in nulliparous women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrauterine devices (IUDs) are among the most effective forms of reversible contraception.
      Numerous studies demonstrate their safety and efficacy in nulliparous women, however, uptake
      of IUDs in this group is low. One of the major barriers to women obtaining IUDs is fear of
      pain during insertion, as studies do demonstrate that nulliparous women experience more pain
      than parous women during IUD insertion. Studies evaluating various methods for pain control
      during IUD insertion have shown conflicting results, leaving the question unanswered as to
      what is the best method to decrease pain during IUD insertion.

      This study aims to evaluate a novel approach to pain control by having women self-insert
      lidocaine gel into the vagina at least 5 minutes prior to IUD insertion. This will overcome
      some of the barriers from other studies where there may not have been ample time for the
      lidocaine to take effect, while at the same time eliminating the need for women to have
      multiple speculum exams. Although this is a novel approach to administering an anesthetic, we
      believe women will be interested in any intervention that may potentially alleviate pain
      during IUD insertion.

      If this study does demonstrate that pain is decreased with self-inserted lidocaine compared
      to placebo gel, this will potentially eliminate one large barrier to nulliparous women
      receiving IUDs. Increased uptake of highly effective contraception in nulliparous women is
      just one of the many steps necessary towards decreasing unintended pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain From Baseline to IUD Insertion</measure>
    <time_frame>change in pain score from baseline (before IUD insertion) to time of IUD insertion</time_frame>
    <description>To assess change in pain from baseline to IUD insertion measured on a visual analog scale (VAS) from 0 mm (no pain) to 100 mm (worst pain in patient's life). This pain assessment was prior to (baseline) and at the time of IUD insertion following vaginal self-administration of study gel (either 2% lidocaine gel or placebo gel).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Patient Experience of Self-inserting the Intravaginal Study Gel Prior to IUD</measure>
    <time_frame>After inserting the gel but prior to IUD insertion</time_frame>
    <description>Number of participants who rated self-application of study gel as &quot;some what easy&quot; or &quot;very easy&quot; on Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of IUDs Considered by Physicians Easy to Insert</measure>
    <time_frame>Directly after IUD insertion</time_frame>
    <description>The physician who conducted the study visit and IUD insertion was asked about the difficulty/ease in placing the IUD immediately following the procedure and the percentage of IUD insertions considered to be &quot;easy&quot; was calculated for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Pain Medication up to 7 Days</measure>
    <time_frame>7 days post-insertion</time_frame>
    <description>Number of women taking pain medication for at least one day following IUD insertion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group 1: Intravaginal 2% lidocaine gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravaginal insertion of 4mL of 2% lidocaine gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Intravaginal placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Intravaginal insertion of 4mL 2% lidocaine gel</description>
    <arm_group_label>Group 1: Intravaginal 2% lidocaine gel</arm_group_label>
    <other_name>Lidocaine Jelly</other_name>
    <other_name>Lidocaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>KY Jelly</description>
    <arm_group_label>Group 2: Intravaginal placebo gel</arm_group_label>
    <other_name>K-Y Jelly</other_name>
    <other_name>water based lubricant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks
             gestational age

          -  Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD
             (Cu-IUD)

          -  No history of pregnancy in the last 6 weeks

          -  Able to provide written informed consent in English and comply with all study
             procedures

        Exclusion criteria:

          -  Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics

          -  Prior failed IUD insertion

          -  Prior IUD use

          -  Use of narcotic or benzodiazepine medication within the last 24 hours

          -  U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4
             classification for use of an IUD

          -  Positive pregnancy test or reasonable risk of pregnancy due to unprotected
             heterosexual intercourse since the last menstrual period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel B Rapkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <results_first_submitted>May 20, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2016</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sharon Achilles</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Intrauterine Device</keyword>
  <keyword>Pain</keyword>
  <keyword>Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 79 women presenting for IUD insertion at OPC, UPP, and GMO were approached for participation.</recruitment_details>
      <pre_assignment_details>2 patients were removed from the study. Patients were considered screen failures before randomization to an arm.
18 declined participation; 10 (56%) reported “time concerns” as their primary reason for declining.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
          <description>4 ml of 2% lidocaine gel for self vaginal insertion</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Intravaginal Placebo Gel</title>
          <description>Intravaginal insertion of 4ml of placebo gel (K-Y Jelly)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28">1 subject withdrew consent at time of uterine sound attempt due to intolerable pain</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomization is blinded.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
          <description>4mL of 2% lidocaine gel for vaginal self-administration
)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Intravaginal Placebo Gel</title>
          <description>4mL placebo gel (K-Y Jelly) for vaginal self-administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Randomization was blinded.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 14-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain From Baseline to IUD Insertion</title>
        <description>To assess change in pain from baseline to IUD insertion measured on a visual analog scale (VAS) from 0 mm (no pain) to 100 mm (worst pain in patient’s life). This pain assessment was prior to (baseline) and at the time of IUD insertion following vaginal self-administration of study gel (either 2% lidocaine gel or placebo gel).</description>
        <time_frame>change in pain score from baseline (before IUD insertion) to time of IUD insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
            <description>Intravaginal insertion of 4mL of 2% lidocaine gel
Placebo: KY Jelly</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Intravaginal Placebo Gel</title>
            <description>Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
Lidocaine: Intravaginal insertion of 5mL 2% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain From Baseline to IUD Insertion</title>
          <description>To assess change in pain from baseline to IUD insertion measured on a visual analog scale (VAS) from 0 mm (no pain) to 100 mm (worst pain in patient’s life). This pain assessment was prior to (baseline) and at the time of IUD insertion following vaginal self-administration of study gel (either 2% lidocaine gel or placebo gel).</description>
          <units>change in visual analog scale score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="71"/>
                    <measurement group_id="O2" value="68" lower_limit="58" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Patient Experience of Self-inserting the Intravaginal Study Gel Prior to IUD</title>
        <description>Number of participants who rated self-application of study gel as &quot;some what easy&quot; or &quot;very easy&quot; on Likert scale</description>
        <time_frame>After inserting the gel but prior to IUD insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
            <description>Intravaginal insertion of 4mL of 2% lidocaine gel
Placebo: KY Jelly</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Intravaginal Placebo Gel</title>
            <description>Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
Lidocaine: Intravaginal insertion of 5mL 2% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Patient Experience of Self-inserting the Intravaginal Study Gel Prior to IUD</title>
          <description>Number of participants who rated self-application of study gel as &quot;some what easy&quot; or &quot;very easy&quot; on Likert scale</description>
          <units>participants who found gel easy to use</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of IUDs Considered by Physicians Easy to Insert</title>
        <description>The physician who conducted the study visit and IUD insertion was asked about the difficulty/ease in placing the IUD immediately following the procedure and the percentage of IUD insertions considered to be &quot;easy&quot; was calculated for each study group.</description>
        <time_frame>Directly after IUD insertion</time_frame>
        <population>Participants in each group self-administered the study gel as per instruction followed by insertion of the IUD by the physician 5 to 15 minutes later.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
            <description>Intravaginal insertion of 4mL of 2% lidocaine gel
Lidocaine: Intravaginal insertion of 4mL 2% lidocaine gel</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Intravaginal Placebo Gel</title>
            <description>Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
Placebo: KY Jelly</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of IUDs Considered by Physicians Easy to Insert</title>
          <description>The physician who conducted the study visit and IUD insertion was asked about the difficulty/ease in placing the IUD immediately following the procedure and the percentage of IUD insertions considered to be &quot;easy&quot; was calculated for each study group.</description>
          <population>Participants in each group self-administered the study gel as per instruction followed by insertion of the IUD by the physician 5 to 15 minutes later.</population>
          <units>percentage of insertions declared easy</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="69" upper_limit="96"/>
                    <measurement group_id="O2" value="64" lower_limit="44" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Pain Medication up to 7 Days</title>
        <description>Number of women taking pain medication for at least one day following IUD insertion</description>
        <time_frame>7 days post-insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Intravaginal 2% Lidocaine Gel</title>
            <description>4 ml of 2% lidocaine gel for self vaginal insertion</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Intravaginal Placebo Gel</title>
            <description>Intravaginal insertion of 4ml of placebo gel (K-Y Jelly)</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Pain Medication up to 7 Days</title>
          <description>Number of women taking pain medication for at least one day following IUD insertion</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Intravaginal insertion of 4mL placebo gel
Placebo: KY Jelly</description>
        </group>
        <group group_id="E2">
          <title>Study Drug</title>
          <description>Intravaginal insertion of 4mL 2% lidocaine gel
Lidocaine: Intravaginal insertion of 4mL 2% lidocaine gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Intolerable Pain</sub_title>
                <description>Pain at time of IUD insertion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dionne Best</name_or_title>
      <organization>UPittsburgh</organization>
      <phone>412-641-5496</phone>
      <email>dbest@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

